Predict your next investment

Private Equity
jvcmanagement.com

See what CB Insights has to offer

Investments

6

About JVC Investment Partners

JVC Investment Partners is a private investment firm focusing on low middle-market and growth platforms in the health care industry.

JVC Investment Partners Headquarter Location

650 Dundee Road Suite 380

Northbrook, Illinois, 60062,

United States

847-960-3840

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest JVC Investment Partners News

ImmPACT Bio Grabs $18M Series A Financing Round

Aug 20, 2020

ImmPACT Bio USA, a company founded in the FutuRx incubator located in Ness Ziona, Israel, developing novel cell therapies for treating cancer, today announced the closing of a US$ 18 million equity financing round. The financing included OrbiMed, Johnson & Johnson Innovation - JJDC, Inc., Takeda Ventures, Inc., RM Global Partners (RMGP) BioPharma Investment Fund, Novartis Venture Fund, Bukwang Pharmaceutical, Hayan Health Networks, Inc., and JVC Investment Partners. ImmPACT Bio USA Inc. is developing a novel set of engineered T-cell therapeutics that target loss of genes in solid tumors. The company was founded based on the insights of Prof. Gideon Gross (Migal Research Institute), who collaborated with Prof. Zelig Eshhar to design the first Chimeric Antigen Receptor technologies for T-cells (CAR T). While CAR-T drugs have provided meaningful breakthroughs for the treatment of some hematologic malignancies, little progress has been made in applying the technology to solid tumors. Such diseases are rarely characterized by the over-expression of tumor-selective antigens, but genomic analyses have revealed many mechanisms for loss of expression. Founder Prof. Gideon Gross explains ImmPACT's origins by observing, "Engineered cells have progressed tremendously in lymphomas and leukemias, in large part because lymphocytes have very selective targets. We will need new targeting strategies to tackle solid tumors, as few selective targets have been discovered, and antigens are almost always shared by indispensable tissues." Prof. Gross ultimately realized that, "Many solid tumors demonstrate genetic losses due to abnormal chromosomal maintenance - a fact that can be utilized to design new types of cellular immuno-oncology drugs." "We have built a world-class team and a promising pipeline to realize Prof. Gross' vision of targeting loss-of-gene features of solid tumors. We look forward to working with our investors to advance this pipeline and make the company a success," said Rick Kendall, Ph.D., CEO of ImmPACT Bio USA Inc. About ImmPACT Bio ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The company was founded based on the research of Prof. Gideon Gross of the Migal Research Institute and has been incubated in the FutuRx incubator since 2017. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.

JVC Investment Partners Investments

6 Investments

JVC Investment Partners has made 6 investments. Their latest investment was in NewAmsterdam Pharma as part of their Series A on January 1, 2021.

CBI Logo

JVC Investment Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/14/2021

Series A

NewAmsterdam Pharma

$196M

Yes

2

8/5/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

6/30/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

7/29/2019

Series C

Subscribe to see more

$99M

Subscribe to see more

10

2/27/2017

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/14/2021

8/5/2020

6/30/2020

7/29/2019

2/27/2017

Round

Series A

Series A

Series B

Series C

Series C

Company

NewAmsterdam Pharma

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$196M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

10

10

10

JVC Investment Partners Team

1 Team Member

JVC Investment Partners has 1 team member, including current Chief Executive Officer, President, David N Jonas.

Name

Work History

Title

Status

David N Jonas

Chief Executive Officer, President

Current

Name

David N Jonas

Work History

Title

Chief Executive Officer, President

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.